Can patients still get Bexxar today?
Bexxar (tositumomab and iodine I-131 tositumomab) is not widely available through routine use today. In practice, many health systems shifted away from it after related products were withdrawn and newer options became standard for certain lymphoma patients.
What does “still be used” mean—licensed, available, or in clinical guidelines?
Whether Bexxar can be used depends on which of these you mean:
- Licensed availability in a country/region (regulatory status).
- Practical availability through suppliers/pharmacies and cancer centers.
- Whether it’s recommended versus replaced by newer regimens (clinical practice).
If you tell me your country (or the country where you’re being treated) and the lymphoma type/stage, I can narrow down which “still” applies.
Why did use of Bexxar decline?
Bexxar was a targeted radioimmunotherapy used in certain settings of non-Hodgkin lymphoma. Over time, newer treatments and treatment sequences reduced reliance on older radioimmunotherapy options, and availability issues made it harder for clinicians to use when alternatives worked.
What alternatives are typically used instead?
Patients and oncologists who would otherwise consider older radioimmunotherapy options often look to currently available standards of care for the same lymphoma subtype and treatment line. The right substitute depends heavily on:
- The specific lymphoma diagnosis
- Prior treatments
- Whether the goal is initial therapy, relapse treatment, or consolidation
How to check if it can be used in your case right now
The fastest way is to ask the treating center (or your oncologist) about:
- Whether they can obtain Bexxar from their authorized channels
- Whether your diagnosis still matches any approved/standard indications they use
- What their equivalent in-current-practice option is if Bexxar is unavailable
If you share your location and lymphoma details, I’ll help you frame the exact questions to ask and identify the most likely current alternatives.